{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T04:45:45Z","timestamp":1791693945580,"version":"4.3.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Helicobacter pylori<\/jats:italic> infection is a primary global health concern. However, the widespread use of antibiotics, particularly macrolides such as clarithromycin, has increased resistance among <jats:italic>H. pylori<\/jats:italic> strains. This study aimed to investigate the prevalence of macrolide resistance in <jats:italic>H. pylori<\/jats:italic> in different world regions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic literature search was performed using the appropriate search syntax after searching PubMed, Embase, Web of Science, and Scopus databases between May 2015 and December 2023. Statistical analysis was performed using Pooled and random effects model in <jats:italic>R<\/jats:italic> and the metafor package.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7,768 articles were retrieved. After a thorough evaluation, 155 studies (by 178 reports) were finally eligible for inclusion in this systematic review and meta-analysis. According to the results, the majority of studies (178 reports from 43 countries) assessed clarithromycin susceptibility, with a pooled prevalence of 33.3% and high heterogeneity between studies (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200998.57%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The rate of erythromycin resistance was moderate (22.8%, 10 reports), while azithromycin resistance was 34.4% (4 reports). Subgroup analysis revealed significant differences in the prevalence of resistance based on geographic location, continent, and year of publication. Clarithromycin resistance increased from 29.1% (2015\u20132019) to 36.5% (2020\u20132023).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights the critical challenges of macrolide resistance in treating <jats:italic>H. pylori<\/jats:italic> infection. The high prevalence and geographic variation underscore the need for tailored treatment strategies based on regional resistance patterns. Furthermore, continuously monitoring resistance trends and investigating contributing factors are essential to optimize treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero<\/jats:ext-link>; CRD42024557749.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2024.1481763","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:04:35Z","timestamp":1730271875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Insights into Helicobacter pylori macrolide resistance: a comprehensive systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Safoura","family":"Morad Kasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mofid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Navidifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Golab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Parvizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Badmasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Sholeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Beig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4251\/wjgo.v7.i12.455","article-title":"Helicobacter pylori in gastric carcinogenesis","volume":"7","author":"Ahn","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00203-023-03639-0","article-title":"Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents","volume":"205","author":"Al-Fakhrany","year":"2023","journal-title":"Arch. Microbiol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/microorganisms12010222","article-title":"Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies","volume":"12","author":"Ali","year":"2024","journal-title":"Microorganisms"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jgh3.12843","article-title":"Management of Helicobacter pylori infection","volume":"7","author":"Aumpan","year":"2023","journal-title":"JGH Open"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1089\/mdr.2022.0146","article-title":"Antibiotic resistance of Helicobacter pylori in Turkey: a systematic review and Meta-analysis","volume":"29","author":"Aya\u015f","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/antibiotics13050396","article-title":"Exploring the molecular mechanisms of macrolide resistance in laboratory mutant Helicobacter pylori","volume":"13","author":"Aya\u015f","year":"2024","journal-title":"Antibiotics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/ajg.2014.24","article-title":"The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America","volume":"109","author":"Camargo","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/antibiotics12020191","article-title":"Helicobacter pylori infection: current status and future prospects on diagnostic, therapeutic and control challenges","volume":"12","author":"Elbehiry","year":"2023","journal-title":"Antibiotics"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s1473-3099(06)70627-2","article-title":"Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications","volume":"6","author":"Gerrits","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and Meta-analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and Meta-analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e12960","DOI":"10.1111\/hel.12960","article-title":"Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: a retrospective study in Ningxia","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989x.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol. Methods"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5009\/gnl220429","article-title":"Optimizing Helicobacter pylori treatment: an updated review of empirical and susceptibility test-based treatments","volume":"17","author":"Ishibashi","year":"2023","journal-title":"Gut Liver"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12879-018-3099-4","article-title":"The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis","volume":"18","author":"Jaka","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"221032","DOI":"10.7754\/Clin.Lab.2022.221032","article-title":"Global estimate of clarithromycin resistance in clinical isolates of Helicobacter pylori: a systematic review and Meta-analysis","volume":"69","author":"Khoshnood","year":"2023","journal-title":"Clin. Lab."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/antibiotics9080436","article-title":"Best Helicobacter pylori eradication strategy in the era of antibiotic resistance","volume":"9","author":"Kim","year":"2020","journal-title":"Antibiotics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/s41467-021-22557-7","article-title":"Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides","volume":"12","author":"Kocsm\u00e1r","year":"2021","journal-title":"Nat. Commun."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jmii.2021.03.006","article-title":"Multidrug resistance: the clinical dilemma of refractory Helicobacter pylori infection","volume":"54","author":"Kuo","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1128\/aac.49.4.1600-1603.2005","article-title":"Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability","volume":"105","author":"Luther","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jclinepi.2020.06.039","article-title":"Quality assessment of prevalence studies: a systematic review","volume":"127","author":"Migliavaca","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"17562848231167284","DOI":"10.1177\/17562848231167284","article-title":"Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection","volume":"16","author":"Moss","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref27","year":"2018"},{"key":"ref9001","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/meg.0000000000002733","article-title":"High antibiotic resistance rates in Helicobacter pylori strains in Turkey over 20 years: implications for gastric disease treatment","volume":"36","author":"Sar\u0131kaya","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and Meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/jgh.15352","article-title":"Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: a systematic review and meta-analysis","volume":"36","author":"Schubert","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e15121","DOI":"10.7717\/peerj.15121","article-title":"The prevalence of clarithromycin-resistant Helicobacter pylori isolates: a systematic review and meta-analysis","volume":"11","author":"Sholeh","year":"2023","journal-title":"PeerJ"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e12730","DOI":"10.1111\/hel.12730","article-title":"The increasing antimicrobial resistance of Helicobacter pylori in Iran: a systematic review and meta-analysis","volume":"25","author":"Sholeh","year":"2020","journal-title":"Helicobacter"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.1002\/0470870168.ch6","article-title":"Regression methods to detect publication and other Bias in Meta-analysis","volume-title":"Publication bias in meta-analysis","author":"Sterne","year":"2005"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2020.05.077","article-title":"Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan","volume":"97","author":"Vilaichone","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jgar.2023.05.014","article-title":"Primary antibiotic resistance in Helicobacter pylori in China: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17474124.2019.1542299","article-title":"The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal","volume":"13","author":"Wu","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/jac\/37.3.473","article-title":"Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro","volume":"37","author":"Xia","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1089\/mdr.2017.0292","article-title":"Antibiotic resistance of Helicobacter pylori in Iranian children: a systematic review and Meta-analysis","volume":"24","author":"Yousefi-Avarvand","year":"2018","journal-title":"Microb. Drug Resist."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2020.08.011","article-title":"Helicobacter pylori infection and autoimmune diseases; is there an association with systemic lupus erythematosus, rheumatoid arthritis, autoimmune atrophy gastritis and autoimmune pancreatitis? A systematic review and meta-analysis study","volume":"54","author":"Youssefi","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.21037\/atm.2016.03.36","article-title":"Residuals and regression diagnostics: focusing on logistic regression","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/jac\/dkaa302","article-title":"Mutations of Helicobacter pylori RdxA are mainly related to the phylogenetic origin of the strain and not to metronidazole resistance","volume":"75","author":"Zhang","year":"2020","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1481763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T07:04:38Z","timestamp":1730271878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1481763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":43,"alternative-id":["10.3389\/fmicb.2024.1481763"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1481763","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1481763"}}